p-Tau217 Adaptive Dosing Protocol

📖 Wiki Page

idea1997 wordssynced 2026-04-02

Rank: 19 | Score: 80/100

Overview

flowchart TD p_Tau217_Adaptive_Dosing_Proto["p-Tau217 Adaptive Dosing Protocol"] p_Tau217_Adaptive_Dosing_Proto["Rank"] p_Tau217_Adaptive_Dosing_Proto -->|"related to"| p_Tau217_Adaptive_Dosing_Proto style p_Tau217_Adaptive_Dosing_Proto fill:#81c784,stroke:#333,color:#000 p_Tau217_Adaptive_Dosing_Proto["Score"] p_Tau217_Adaptive_Dosing_Proto -->|"related to"| p_Tau217_Adaptive_Dosing_Proto style p_Tau217_Adaptive_Dosing_Proto fill:#81c784,stroke:#333,color:#000 p_Tau217_Adaptive_Dosing_Proto["Protocol"] p_Tau217_Adaptive_Dosing_Proto -->|"related to"| p_Tau217_Adaptive_Dosing_Proto style p_Tau217_Adaptive_Dosing_Proto fill:#81c784,stroke:#333,color:#000 style p_Tau217_Adaptive_Dosing_Proto fill:#4fc3f7,stroke:#333,color:#000

[p-Tau217](/biomarkers/p-tau-217) Adaptive Dosing Protocol is a biomarker-guided therapeutic strategy that uses longitudinal p-tau217 (phosphorylated [tau](/proteins/tau) at threonine 217) measurements to dynamically titrate anti-tau immunotherapy dosing. This approach addresses a critical challenge in tau-targeted therapies: the need for personalized dosing based on individual pathological burden and treatment response["@palmqvist2021"][@janelidze2021].

Biological Background

p-Tau217 as a Biomarker

Phosphorylated tau at threonine 217 (p-tau217) has emerged as one of the most promising fluid biomarkers for Alzheimer's disease:

...

Rank: 19 | Score: 80/100

Overview

Mermaid diagram (expand to render)

Biological Background

p-Tau217 as a Biomarker

Phosphorylated tau at threonine 217 (p-tau217) has emerged as one of the most promising fluid biomarkers for Alzheimer's disease:

Specificity: p-tau217 shows high specificity for Alzheimer's disease compared to other neurodegenerative conditions[@palmqvist2021]
Sensitivity: Detectable in cerebrospinal fluid (CSF) and plasma years before clinical symptoms
Correlation: Strong correlation with cortical tau burden as measured by PET[@janelidze2021]
Dynamic range: Levels change in response to disease progression and therapeutic intervention

Rationale for Adaptive Dosing

Current anti-tau immunotherapy approaches use fixed dosing schedules that fail to account for:

Individual variation in tau pathology burden
Differential response rates to treatment
Potential for overtreatment in early-stage patients
Undertreatment in rapid progressors

An adaptive dosing protocol based on p-tau217 trajectories can optimize:

Efficacy: Maintain therapeutic benefit while avoiding underdosing
Safety: Minimize dose-related adverse events
Cost: Reduce unnecessary drug exposure
Precision: Enable personalized treatment algorithms

Scoring (10-Dimension Rubric)

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 8 | Adaptive dosing protocols for tau immunotherapy are in early development; p-tau217 as dynamic biomarker is emerging |
| Mechanistic Rationale | 9 | Strong biological basis linking p-tau217 to treatment response |
| Root-Cause Coverage | 8 | Addresses tau pathology but uses biomarker rather than direct mechanism |
| Delivery Feasibility | 9 | Uses existing anti-tau antibodies; only adds biomarker monitoring |
| Safety Plausibility | 8 | Adaptive dosing could improve safety by reducing unnecessary exposure |
| Combinability | 9 | Highly compatible with other anti-tau, anti-amyloid, or neuroprotective approaches |
| Biomarker Availability | 9 | p-tau217 assays are commercially available and validated |
| De-risking Path | 8 | Clear regulatory pathway using existing antibody frameworks |
| Multi-disease Potential | 7 | Primarily AD-focused; some applicability to primary tauopathies |
| Patient Impact | 8 | Personalized dosing improves outcomes and reduces adverse events |
| Total | 81/100 | Calculated from 10 dimensions |

Implementation Strategy

Phase 1: Baseline Assessment

Establish baseline p-tau217 levels at screening
Confirm amyloid and/or tau positivity per inclusion criteria
Define individual "responder" profile

Phase 2: Initial Treatment

Standard induction dosing (e.g., loading dose series)
p-tau217 sampling at weeks 4, 8, 12, 16

Phase 3: Adaptive Titration

Responder algorithm: If p-tau217 decline >30% from baseline, maintain current dose
Partial responder: If decline 15-30%, consider dose escalation
Non-responder: If decline <15%, re-evaluate or add combination therapy

Phase 4: Maintenance

Ongoing p-tau217 monitoring every 3-6 months
Dose adjustments based on sustained response or relapse

De-risking Path

Technical De-risking

Use established anti-tau antibodies (e.g., gosuranemab, tilavonemab, semorinemab) as platform

Partner with p-tau217 assay providers (Roche, Fujirebio, ALZpath)

Develop point-of-care plasma p-tau217 for decentralized monitoring

Clinical De-risking

Start with Phase 2 adaptive dosing substudy in ongoing trials

Use umbrella trial design to test multiple adaptive algorithms

Engage FDA/BMH early on biomarker-driven endpoints

Commercial De-risking

Position as companion diagnostic + therapeutic combo

Value proposition: improved efficacy + reduced adverse events = better payor economics

Risks and Mitigation

Key Risks

p-tau217 assay standardization: Different assays (Roche, Lilly, Simoa) use different epitopes and yield different values

Mitigation: Standardize to single assay for clinical use; develop conversion algorithms

Adaptive dosing overtreatment: Frequent dose adjustments based on biomarker may lead to over-treatment

Mitigation: Set clear minimum/maximum dose boundaries; require sustained elevation for escalation

Drug-biomarker interaction: Anti-amyloid drugs may affect p-tau217 independently of clinical effect

Mitigation: Use multiple tau biomarkers (p-tau181, p-tau231) for validation

Patient burden: Frequent biomarker sampling (CSF or blood) may reduce compliance

Mitigation: Develop less invasive sampling methods; use dried blood spot testing

Clinical validation: P-tau217 as adaptive dosing biomarker needs prospective validation

Mitigation: Include biomarker validation endpoints in Phase 3 trials

Timeline

| Phase | Duration | Milestones |
|-------|----------|------------|
| Assay Standardization | 6 months | Single-platform validation |
| Phase 2 Trial | 18 months | Biomarker-guided dosing |
| Phase 3 Trial | 24 months | Registrational trial |

Estimated Cost

| Phase | Estimated Cost | Notes |
|-------|-----------------|-------|
| Assay Development | $2-3M | Standardization |
| Phase 2 | $15-20M | Adaptive design |
| Phase 3 | $30-40M | Registration |
| Total | $47-63M | End-to-end |

Key Academic Centers

University of Gothenburg — Henrik Zetterberg
Washington University — Randall Bateman
Mayo Clinic — Michelle Mielke

Potential Partner Companies

Roche — Elecsys p-tau217
Eli Lilly — p-tau217 assays
Quanterix — Simoa platform
Biogen — AD pipeline

Actionable Next Steps

Lab Experiments

p-Tau217 assay validation: Run head-to-head comparison of plasma p-tau217 from multiple vendors (Roche, Fujirebio, ALZpath, Quanterix) in 200+ AD patient samples to establish assay interchangeability and correlation with CSF p-tau217

Adaptive algorithm development: Using historical data from failed anti-tau trials (gosuranemab, tilavonemab, semorinemab), develop machine learning models to predict responders based on baseline p-tau217, age, and [APOE](/proteins/apoe) status

Proof-of-concept in animal models: Test adaptive dosing in tau transgenic mice (P301S, 3xTg-AD) with serial plasma p-tau217 sampling to correlate with brain tau PET

Clinical Protocol Design

Phase 2 adaptive substudy: Propose 48-week adaptive dosing substudy within existing anti-tau trial (e.g., tau Axon registry), comparing standard fixed dosing vs. p-tau217-guided titration

Enrichment strategy: Use baseline p-tau217 >60 pg/mL as enrollment criterion to ensure adequate pathological burden

Endpoint selection: Primary endpoint = change in global cognition (ADAS-Cog13) at week 48; key secondary = change in plasma p-tau217, tau PET SUVr

Adaptive design features: Pre-specified interim analysis at week 24 for sample size re-estimation or dose-escalation trigger

Company Partnership Opportunities

Anti-tau antibody developers:

Eli Lilly (semorimenab) — already has tau pipeline
Biogen/AstraZeneca (gosuranemab) — partnered on tau
AbbVie — seeking differentiation in crowded space

2. Diagnostic partners:

Roche Diagnostics — Neurop sekter p-tau217 platform
Fujirebio — Lumipulse CSF p-tau217
C2N Diagnostics — PrecivityAD blood test

3. Digital health: AiCare, Linus Health for integrated biomarker tracking

Grant Targets

NIH NIA:

R21 (Exploratory/Developmental): "p-Tau217-guided adaptive anti-tau dosing in early AD" (~=K over 2 years)
U01 (Phase 2 trial planning): "Adaptive Dosing Platform for Tau Immunotherapy" (~M over 3 years)
SBIR/STTR (with diagnostic partner): Companion diagnostic development

2. Foundations:

BrightFocus Foundation — A2022015N (AD biomarker trials)
Alzheimer's Association — Part the Cloud (Phase 1/2 clinical trials)
Michael J. Fox Foundation — therapeutic biomarker studies

3. International:

EU Joint Programme — Neurodegenerative Disease Research (JPND)
UK Dementia Research Institute

Implementation Roadmap

Phase 1: Assay Validation & Algorithm Development (Months 1-18)

Cost: $2.5-4M

| Milestone | Timeline | Cost | Risk |
|-----------|----------|------|------|
| p-Tau217 multi-vendor comparison study | Months 1-9 | $800K | Low |
| Adaptive algorithm ML model development | Months 6-15 | $1.2M | Medium |
| Pre-IND meeting with FDA | Month 12 | $200K | Low |
| IND-enabling pharmacology summary | Months 12-18 | $500K | Low |

Key Risks:

Assay variability could require additional validation (mitigation: include 3+ vendors)
Algorithm accuracy may need iteration (mitigation: iterative training with real trial data)

Phase 2: Phase 2 Adaptive Dosing Trial (Months 15-36)

Cost: $8-15M

| Milestone | Timeline | Cost | Risk |
|-----------|----------|------|------|
| Site initiation (15-20 sites US/EU) | Months 15-18 | $1.5M | Low |
| Patient enrollment (n=200 adaptive) | Months 18-30 | $6M | Medium |
| Interim analysis (week 48) | Month 30 | $500K | Medium |
| Final analysis (week 96) | Month 36 | $1M | Low |

Key Risks:

Enrollment could miss targets (mitigation: inclusion of international sites)
Adaptive algorithm may need adjustment (mitigation: pre-specified adaptation rules)

Phase 3: Phase 3 Registration Trial (Months 30-60)

Cost: $35-55M

| Milestone | Timeline | Cost | Risk |
|-----------|----------|------|------|
| Phase 3 protocol finalization | Months 30-33 | $2M | Low |
| Global enrollment (n=800-1000) | Months 33-48 | $25M | Medium |
| Phase 3 readout | Month 56 | $5M | Medium |
| NDA/MAA filing and approval | Months 56-60 | $8M | Low |

Key Risks:

Phase 2/3 regulatory feedback may require design changes
Competition from standard-of-care anti-tau antibodies

Total Program Cost: $45-74M over 60 months

Risk-Adjusted Scenarios

| Scenario | Probability | Cost Impact |
|----------|-------------|-------------|
| Best case (accelerated approval) | 15% | $35M |
| Base case | 50% | $55M |
| Slow enrollment + one protocol amendment | 25% | $75M |
| Program pivot (new target) | 10% | +$20M |

Academic Center Recommendations

US: Mayo Clinic (tau biomarker expertise), UC Irvine (ADRC), Washington University (DIAN)

EU: Karolinska Institutet (Sweden), University of Cambridge (UK), Charité Berlin (Germany)

Industry Partners: Thermo Fisher (assay manufacturing), WuXi AppTec (CRO)

Decision Gates

| Gate | Criteria | Go/No-Go |
|------|----------|----------|
| Phase 1→2 | Positive assay validation + FDA feedback | Go if assay CV <15% |
| Phase 2→3 | Week 48 p-Tau217 correlation with cognition | Go if r > 0.4, p < 0.01 |
| Registration | Phase 3 interim shows significance | Go if p < 0.025 |

Next Steps

Immediate Actions (0-3 months)

Assay validation protocol: Finalize p-Tau217 assay validation plan with 3 certified labs (Mayo, USC, Copenhagen). Define CV acceptance criteria (<15%).

Regulatory pre-pre-IND meeting: Schedule informal FDA meeting to discuss adaptive dosing framework and biomarker-driven design.

Site feasibility assessment: Evaluate 10 potential Phase 1 sites for early-phase biomarker endpoint experience.

Near-term Milestones (3-12 months)

Assay validation study: Complete inter-assay and intra-assay CV testing across 3 labs using standardized plasma samples.

Phase 1 protocol finalization: Design adaptive dosing Phase 1 with biomarker endpoints (p-Tau217, p-Tau181, total tau).

Patient recruitment materials: Develop genetics-first recruitment strategy for APOE4 carriers and sporadic AD.

Research Gaps to Address

Establish p-Tau217 cutoff thresholds for treatment response (not just diagnosis)
Validate correlation between plasma p-Tau217 and CSF p-Tau217 in treatment-naive subjects
Assess assay performance in diverse ethnic populations

Collaboration Opportunities

Academic: Join DIAN-TU consortium for adaptive trial design expertise
Pharma: Partner with tau immunotherapy companies ( Lilly, Roche) for combination trial potential
Diagnostic: Work with ALZpath and Quanterix on assay standardization

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Cross-Links

[Tau Protein](/proteins/tau)
[Biomarkers for Neurodegeneration](/mechanisms/neurodegeneration-biomarkers)
[p-Tau217 Biomarker](/mechanisms/ptau217-biomarker)
[Alzheimer's Disease](/diseases/alzheimers-disease)

Rubric Score

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 7/10/10 | p-tau217 as biomarker is breakthrough; adaptive dosing is innovative |
| Mechanistic Rationale | 6/10/10 | Uses biomarker for treatment guidance; addresses pharmacokinetics, not pathology |
| Addresses Root Cause | 6/10/10 | Optimizes drug delivery; indirect effect on disease modification |
| Delivery Feasibility | 7/10/10 | Same as standard dosing; biomarker drives timing |
| Safety Plausibility | 7/10/10 | Enhanced safety monitoring; biomarker-guided dose adjustment |
| Combinability | 7/10/10 | Compatible with any disease-modifying therapy |
| Biomarker Availability | 9/10/10 | p-tau217 is highly validated; accessible via blood test |
| De-risking Path | 8/10/10 | Platform approach; can be applied to multiple drugs |
| Multi-disease Potential | 7/10/10 | Broad applicability across AD therapeutics |
| Patient Impact | 8/10/10 | Could significantly improve therapeutic outcomes and reduce adverse events |
| Total | 72/100 | |

References

[Palmqvist et al, Discriminative accuracy of plasma p-tau217 for Alzheimer disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34047050/)

[Janelidze et al, Plasma p-tau217 predicts in vivo brain pathology and clinical decline (2021)](https://pubmed.ncbi.nlm.nih.gov/34038573/)

📖 View canonical wiki page →

p-Tau217 Adaptive Dosing Protocol

Overview

Biological Background

p-Tau217 as a Biomarker

Overview

Biological Background

p-Tau217 as a Biomarker

Rationale for Adaptive Dosing

Scoring (10-Dimension Rubric)

Implementation Strategy

Phase 1: Baseline Assessment

Phase 2: Initial Treatment

Phase 3: Adaptive Titration

Phase 4: Maintenance

De-risking Path

Technical De-risking

Clinical De-risking

Commercial De-risking

Risks and Mitigation

Key Risks

Timeline

Estimated Cost

Key Academic Centers

Potential Partner Companies

Actionable Next Steps

Lab Experiments

Clinical Protocol Design

Company Partnership Opportunities

Grant Targets

Implementation Roadmap

Phase 1: Assay Validation & Algorithm Development (Months 1-18)

Phase 2: Phase 2 Adaptive Dosing Trial (Months 15-36)

Phase 3: Phase 3 Registration Trial (Months 30-60)

Total Program Cost: $45-74M over 60 months

Risk-Adjusted Scenarios

Academic Center Recommendations

Decision Gates

Next Steps

Immediate Actions (0-3 months)

Near-term Milestones (3-12 months)

Research Gaps to Address

Collaboration Opportunities

See Also

External Links

Cross-Links

Rubric Score

References